These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35681079)

  • 41. Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study.
    Chen C; Dettman EJ; Zhou W; Gozman A; Jin F; Lee LC; Ren Y; Zhou H; Cristescu R; Shao C
    Future Oncol; 2024; 20(31):2357-2370. PubMed ID: 39011875
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Liu YL; Selenica P; Zhou Q; Iasonos A; Callahan M; Feit NZ; Boland J; Vazquez-Garcia I; Mandelker D; Zehir A; Burger RA; Powell DJ; Friedman C; Cadoo K; Grisham R; Konner JA; O'Cearbhaill RE; Aghajanian C; Reis-Filho JS; Weigelt B; Zamarin D
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
    Frey MK; Pothuri B
    Gynecol Oncol Res Pract; 2017; 4():4. PubMed ID: 28250960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery.
    Yi H; Li L; Huang J; Ma Z; Li H; Chen J; Zheng X; Chen J; He H; Song J
    Front Mol Biosci; 2022; 9():906922. PubMed ID: 35769916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
    Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
    J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
    Cristescu R; Liu XQ; Arreaza G; Chen C; Albright A; Qiu P; Marton MJ
    BMC Cancer; 2022 Dec; 22(1):1310. PubMed ID: 36517748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biomarkers for Homologous Recombination Deficiency in Cancer.
    Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD
    J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
    Elze L; van der Post RS; Vos JR; Mensenkamp AR; Pamidimarri Naga S; Hampstead JE; Vermeulen E; Oorsprong M; Hofste T; Simons M; Nagtegaal ID; Hoogerbrugge N; de Voer RM; Ligtenberg MJL
    J Natl Cancer Inst; 2024 Dec; 116(12):1904-1913. PubMed ID: 38960732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
    Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
    Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
    Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures.
    Diossy M; Sztupinszki Z; Borcsok J; Krzystanek M; Tisza V; Spisak S; Rusz O; Timar J; Csabai I; Fillinger J; Moldvay J; Pedersen AG; Szuts D; Szallasi Z
    NPJ Precis Oncol; 2021 Jun; 5(1):55. PubMed ID: 34145376
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
    Manié E; Popova T; Battistella A; Tarabeux J; Caux-Moncoutier V; Golmard L; Smith NK; Mueller CR; Mariani O; Sigal-Zafrani B; Dubois T; Vincent-Salomon A; Houdayer C; Stoppa-Lyonnet D; Stern MH
    Int J Cancer; 2016 Feb; 138(4):891-900. PubMed ID: 26317927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biomarker Assessment of HR Deficiency, Tumor
    Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
    Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.
    Ma J; Shah R; Bell AC; McDermott N; Pei X; Selenica P; Haseltine J; Delsite R; Khan AJ; Lok BH; Ellis MJ; Aft RF; Setton J; Reis-Filho JS; Riaz N; Powell SN
    Int J Radiat Oncol Biol Phys; 2024 Jul; ():. PubMed ID: 38997095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pan-cancer landscape of homologous recombination deficiency.
    Nguyen L; W M Martens J; Van Hoeck A; Cuppen E
    Nat Commun; 2020 Nov; 11(1):5584. PubMed ID: 33149131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional
    Meijer TG; Verkaik NS; Sieuwerts AM; van Riet J; Naipal KAT; van Deurzen CHM; den Bakker MA; Sleddens HFBM; Dubbink HJ; den Toom TD; Dinjens WNM; Lips E; Nederlof PM; Smid M; van de Werken HJG; Kanaar R; Martens JWM; Jager A; van Gent DC
    Clin Cancer Res; 2018 Dec; 24(24):6277-6287. PubMed ID: 30139880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    Rabban JT; Chen LM; Devine WP
    Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer.
    Su R; Liu Y; Wu X; Xiang J; Xi X
    Front Mol Biosci; 2021; 8():762741. PubMed ID: 34869593
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.